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Özet
Amaç: Bu çalışmada, ileri evre yaşlı küçük hücreli dışı akciğer kanseri (KHDAK) 
hastalarında, paklitaksel ve karboplatin (PK) rejiminin etkinliği ve tolerabilite-
si araştırıldı. Gereç ve Yöntem: Evre IIIB (n=11) veya IV (n=34) KHDAK nede-
niyle PK tedavisi alan yaşlı (yaş ≥ 70) 45 hasta retrospektif olarak değerlendi-
rildi. Bulgular: Hastaların 43’ü erkek, 2’si kadın olup ortanca yaşı 75.5 (70-82) 
idi. Yanıt oranı %40’dı. Medyan genel sağkalım süresi ve progresyonsuz sağ-
kalım süresi sırasıyla 13 ay ve 8.5 ay, 1-yıllık sağkalım oranı %51’di. Tedavi 
hastalar tarafından iyi tolere edildi. Grade 3 veya 4 nötropeni (%57.7) en sık 
görülen yan etkiydi. Tedaviye bağlı ölüm görülmedi. Sonuç: PK rejimi ileri evre 
yaşlı KHDAK hastalarının tedavisi için iyi bir alternatif olabilir.         
Anahtar Kelimeler
Karsinom; Küçük Hücreli Dışı; Akciğer; Yaşlı; Kemoterapi 
Abstract
Aim: In this study, the safety and tolerability of paclitaxel and carboplatin 
(PC) regimen in elderly patients with advanced non-small cell lung cancer 
(NSCLC)  was  investigated.  Material  and  Method:  Elderly  patients  (ages 
≥70 years) who received PC for stage III (n=11) or IV (n=34) NSCLC were 
evaluated  retrospectively.  Results:  There  were  43  males  and  2  females, 
with a median age of 75.5 (range, 70-82). The response rate was 40%. 
The median overall survival time and progression-free survival time was 
13 months and 8.5 months, respectively. One-year survival rate was 51%. 
Treatment was well tolerated by the patients. The most frequent side effect 
observed was grade 3 or 4 neutropenia (57.7%). There was no treatment-
related death. Discussion: PC regimen may be a good alternative for the 
treatment of elderly patients with advanced NSCLC. 
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Introduction
Non-small cell lung cancer (NSCLC) accounts for approximately 
85% of all lung cancer. At the time of diagnosis, the majority 
of NSCLC patients already have advanced disease. More than 
50% of NSCLC patients are diagnosed over the age of 65 and 
about 30% over the age of 70 [1]. Systemic chemotherapy plays 
a critical role in improving survival and remains a therapeutic 
option in elderly patients with advanced NSCLC. However, age-
related decreases in organ function, including reductions in re-
nal, hepatic, and bone marrow function, have the potential to 
increase toxicity of chemotherapy in the elderly. Therefore, the 
treatment of elderly patients with advanced NSCLC represents 
a considerable challenge for the practitioner of oncology. The 
best chemotherapy regimen for elderly patients with advanced 
NSCLC is still debated. A recent International expert panel sug-
gested that single-agent chemotherapy with a third-generation 
drug (e. g, vinorelbine, gemcitabine and taxanes) should be rec-
ommended option for unselected elderly NSCLC patients [2].   
Platinum-based  chemotherapy  is  currently  recommended  as 
the standard therapy for patients with advanced NSCLC and 
the combination of paclitaxel and carboplatin (PC) is one of the 
most commonly used chemotherapy regimens for this disease. 
During the past decade, a number of patients 70 years of age 
and over with locally advanced and metastatic NSCLC received 
PC regimen at our hospital. In the present study, we reviewed 
our experience between 2004 and 2008, with elderly patients 
treated with PC.  
Material and Method
We performed a detailed retrospective review of the medical 
records of patients aged ≥70 years with stage IIIB or IV NSCLC 
who received PC regimen between January 2004 and August 
2008 at our hospital. The data on demographic information, 
number of chemotherapy cycles, toxicity, response, and date of 
disease progression and death were collected. All patients were 
staged on the basis of physical examination, chest radiography, 
computed tomography (CT) scan of chest, abdomen, and brain, 
radionuclide scan of bone, and positron emission tomography. 
All patients had histologically or cytologically proven NSCLC, 
and had radiologically measurable disease and adequate hema-
tologic, renal and hepatic function.   
Paclitaxel was received intravenously (i.v.) at a dose of 175 mg/
m2 over 3 h in 500 ml of normal saline and then carboplatin was 
received i.v. at an AUC of 6 mg/ml/min over 60 min in 250 ml of 
normal saline on day 1. Before the administration of paclitaxel, 
the patients were premedicated with dexamethasone (20 mg 
i.v.), ranitidine (50 mg i.v.) and feniramin (45.5 mg i.v.). A 5-HT3 
receptor antagonist was also i.v. administered immediately be-
fore paclitaxel infusion. Chemotherapy courses were repeated 
every three or four weeks. Patients were treated for a maximum 
of six cycles or until intolerable toxicity, disease progression, or 
death. Prophylactic hematologic growth factors were not ad-
ministered routinely.  
Chest  radiography  was  obtained  before  each  cycle,  and  CT 
scans were performed every two or three cycles to evaluate the 
response to chemotherapy. Tumor response was assessed ac-
cording to World Health Organization (WHO) criteria. Toxicity 
was assessed using WHO criteria and the worst toxicity grade 
for each patient in all cycles of chemotherapy was recorded. 
Overall survival was calculated from the date of the first cycle 
of chemotherapy to the date of death from any cause or last 
follow-up visit. Progression-free survival was calculated from 
the date of the first cycle of chemotherapy to the first evidence 
of progression. Survival times were estimated using Kaplan-
Meier method.  
Results
Of 52 patients received PC regimen, 45 were assessable. Seven 
patients were excluded from the study because of insufficient 
clinical data. There were 43 men and 2 women. The median age 
was 75.5 years (range, 70-82). Patient characteristics are sum-
marized in Table 1. Eastern Cooperative Oncology Group perfor-
mance scores were 1 in 24 (53.3%) patients, 0 in 14 (31%), and 
2 in 7 (15.5%) patients. Comorbidity consisted of hypertension 
(33%), chronic obstructive pulmonary disease (17%), and diabe-
tes (13%). Twenty-three patients had squamous cell carcinoma, 
11 had adenocarcinoma, and 1 had large cell carcinoma. The 
histologic subtype of NSCLC was not defined in 10 patients. 
Thirty four patients had stage IV (75.5%) and 11 (24.5%) had 
stage IIIB disease (with pleural effusion or N3 nodal disease) at 
the time of diagnosis. More than half the patients with stage IV 
disease had two or more disease sites.
Response and survival
The median number of chemotherapy cycles received was four 
(range, 1-6). The response could not be evaluated in 3 patients 
because of early death. The overall response rate was 40%. One 
patient (2%) had a complete response, and 16 (38%) had a par-
tial response. 
The median follow up time from diagnosis was 11.8 months. 
The median overall survival (OS) time was 13 months (95% CI, 
9.9-16), and 1-year survival rate was 51%. The median progres-
sion-free survival (PFS) time was 8.5 months (95% CI, 6.7-10.4) 
and, the 1-year progression- free survival rate was 15.5%. 
Toxicity
The most relevant side effects are summarized in Table 2. The 
incidence of grade 3/4 neutropenia was 57.7%. Six patients 




"%&.)
,%4%'6)4-56-'51*6,)2%6-)065
,%4%'6)4-56-'5 11*2%6-)065
+)/)(-%0 :45 4%0+)	
	:)%45
 :)%45
)0()4
%.)
)/%.)
 2)4*14/%0')56%675
	



-561.1+:
!37%/175')..'%4'-01/%
()01'%4'-01/%
%4+)')..'%4'-01/%
#0'.%55-*-)(
!6%+)

$
 
	 



 

 











	




"%&.),)/16,)4%2:619-'-6:
"19-'-6: 4%()

0 
4%()
0 
)76412)0-% 
 
0)/-%  

",41/&1':612)0-% 	 

%75)%81/-6-0+ 	 		
)7412%6,: 
  		
:%.+-%%46,4%.+-% 
 
-%44,)%  		
|  Journal of Clinical and Analytical Medicine 294
Yaşlı Akciğer Kanserli Hastalarda Kemoterapi / Chemotherapy in Elderly Lung Cancer PatientsJournal of Clinical and Analytical Medicine  | 
Yaşlı Akciğer Kanserli Hastalarda Kemoterapi / Chemotherapy in Elderly Lung Cancer Patients
3
were  hospitalized  for  febrile  neutropenia.  Granulocyte-colony 
stimulating factor was used in nearly 60% of the patients. The 
incidences of grade 3/4 anemia and thrombocytopenia were 
relatively low. Twenty-one patients (46.7%) had grade 1/2 neu-
ropathy. No treatment-related death was observed. 
Discussion
In this retrospective study, we evaluated the efficacy and toxic-
ity of PC regimen in elderly patients with advanced NSCLC. The 
rate of response to PC was 40%. The median PFS and OS times 
were 8.5 months and 13 months, respectively. These results are 
comparable with those of other studies investigating activity 
of PC in non-elderly patients [3, 4]. PC was well tolerated in our 
patients. Side effects were generally manageable and did not 
have a significant impact on the quality of life in patients. As 
expected, hematological toxicity was frequent. Nearly 60% of 
our patients experienced grade 3 or 4 neutropenia. However, 
the hematological toxicity was readily managed and of short 
duration and did not result in any treatment-related deaths.  
In a phase II study, Okamoto et al. [5] investigated the efficacy 
and safety of PC in 25 patients aged ≥70 years with chemother-
apy-naive advanced NSCLC. The paclitaxel dose 180 mg/m2) 
and carboplatin doses (AUC=5) they used were slightly different 
from that used in our study. On the other hand, they excluded 
patients if they had an ECOG performance score greater than 1. 
The results of this study were similar to those in our study. The 
median survival time was 12.3 months, and the 1-year survival 
rate was 52%. In a phase II study conducted by Inoue et al. [6], 
40 elderly NSCLC patients received paclitaxel at a dose of 70 
mg/m2 on days 1, 8, 15, and carboplatin at the target dose of 
AUC of six on day 1 every 28 days. The overall response rate 
was 45%. The median survival time was 14 months and the 
1-year survival rate was 62%. The relatively high rate of hema-
tological toxicity was observed in this study. Grade 3 or 4 neu-
tropenia was experienced in 70% of the patients. Subsequently, 
the same authors designated a randomized trial comparing the 
efficacy and safety of these two schedules of PC regimen in 
elderly patients (≥70 years) with advanced NSCLC [7]. Patients 
were randomly assigned to either the weekly arm (70 mg/m2 
paclitaxel on days 1, 8, 15, and carboplatin AUC=6 on day 1) 
or the standard arm (200 mg/m2 paclitaxel and carboplatin 
AUC=6 on day 1). The overall response rate and median PFS 
were 55% and 6 months for the weekly arm and 53% and 5.6 
months for the standard arm. Regarding the safety, the weekly 
regimen was less toxic than the standard regimen. Grade 3-4 
neutropenia and peripheral neuropathy were observed in 41% 
and 0% of the patients in the weekly arm and 88% and 25% 
in the standard arm, respectively. These results are supported 
by Ramalingam et al [8]. They reported similar survival and re-
sponse rates between the weekly regimen and standard regi-
men of PC for elderly patients with advanced NSCLC. 
Several clinical trials using other chemotherapy drugs have been 
reported  recently  for  elderly  patients  with  advanced  NSCLC 
[9-13].  The  response  rates  for  non-platinum-based  single  or 
double-agent  chemotherapeutics  regimens  in  these  studies 
ranged from 16 to 23%, with 1-year survival rates of 27-45%. 
The response rate of 40% and 1-year survival rate of 51% de-
tected in our study thus higher than values obtained in these 
studies. 
We concluded that PC regimen can be used safely and effec-
tively in the treatment of elderly patients with advanced NSCLC. 
The weekly regimen could be considered a good alternative to 
standard 3-weekly regimen in these patients. 
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